16:01 IST
BSE
Capacity Expansion
Aurobindo Pharma Capacity Expansion: ₹1,395 Cr Investment
Aurobindo Pharma's subsidiary, TheraNym Biologics, will invest approximately ₹1395.0 Crore (USD 150M) to establish a new large-scale mammalian manufacturing facility ('Unit 2'). This greenfield project expands an existing CMO relationship with Merck Sharpe & Dohme (MSD) and will house 60 KL of bioreactor capacity.
- Value
- ₹1,395 Cr